Drug intelligence / Profile preview

HPP854

Development stage: Discontinued
Lead developer: High Point Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

HPP854 is an orally active small molecule inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), also known as beta-secretase. It was developed for the treatment of Alzheimer's disease and mild cognitive impairment. By inhibiting BACE1, HPP854 aimed to reduce the production of amyloid-beta peptides implicated in the pathogenesis of Alzheimer's disease. The drug was originally developed by High Point Pharmaceuticals, a spin-off from TransTech Pharma, with vTv Therapeutics also associated with its development. Clinical development reached phase 1 but was discontinued after termination of early trials due to lack of efficacy or other strategic reasons[2][3][4][5].

Targets

BACE1 (Beta-site APP-cleaving enzyme 1)

Beyond the preview

Go deeper on HPP854.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HPP854.

Explore the full profile